Frontlight ResearchEarly access
Taking people in PolandPhase 1
Tests trametinib and gilteritinib in adults with relapsed or hard-to-treat acute leukemia
Tests two drugs, trametinib and gilteritinib, in adults with relapsed or hard-to-treat acute leukemia.
Key facts
- Who runs it
- Instytut Hematologii I Transfuzjologii
- Where
- Gdansk, Katowice, Poznan, Warsaw, and Wrocław, PolandSee the 6 sites
- Registry title
- Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 54 people, planned
- Started
- 28 Jan 2022
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Record updated
- 1 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute leukemia (ALL or AML) that came back or did not respond to treatment, who have no other treatment options.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute lymphoblastic (ALL) or acute myeloid (AML) leukemia that has relapsed or did not respond to treatment, in people who cannot have treatment meant to remove all of the disease.
- Earlier treatment
- People must have no other treatment options available.
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Poland
- Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
- Samodzielny Publiczny Szpital Kliniczny Im.Adrzeja Mieleckiego Slaskiego Uniwersytetu MedycznegoKatowice, PolandTaking people
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych I Administracji W Poznaniu Im. Prof. Ludwika BierkowskiegoPoznan, PolandTaking people
- Uniwersytet Medyczny w PoznaniuPoznan, PolandTaking people
- Instytut Hematologii I TransfuzjologiiWarsaw, PolandTaking people
- Uniwersytet Medyczny we WrocławiuWrocław, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests trametinib and gilteritinib in adults with relapsed or hard-to-treat acute leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 1 October 2026